At BioVertex Consulting, the past few months have been rewarding, working across diverse healthcare innovation stakeholders across the globe. From Business Development, to Venture Coaching, to VC advisory, each project reflects how strategic, hands-on support can help bridge science and execution.
Business Development for an AI Platform Company
We've been supporting a cutting-edge AI platform company specializing in protein design and engineering. The work focuses on strategic business development by meeting new customer acquisition objectives through sales and marketing activities. The goal has been to connect their technological edge of deep learning models that accelerate protein optimization with real-world problems faced by therapeutic, industrial, and synthetic biology companies. It's been an exciting space where AI meets experimental biology, and the potential for redefining protein discovery workflows is immense.
Key Takeaway: Technical excellence alone does not drive partnerships. Translating deep technology into the language of the customer - their problem, their workflow, their risk profile - is what opens doors. Science is the foundation; strategy is the bridge.
Venture Coaching for Early-Stage Academic Teams
In parallel, we've been coaching academic innovators as they explore pathways to translate their science into ventures. Many of these teams are in the early stages of ideation — still defining their commercial hypotheses. Our role involves guiding them through venture exploration and stakeholder engagement to clarify their value proposition, link it to the unmet need, identify potential customers or partners, and build an early narrative that resonates beyond the lab. It's incredibly fulfilling to see researchers begin to think like founders, translating their passion for discovery into impact-focused ventures.
Guiding Academic Teams from Lab Bench to Investment Readiness
Through structured venture exploration, we helped teams articulate a compelling mission and vision, conduct rigorous market and stakeholder assessments, define a Target Product Profile (TPP), and build an integrated development roadmap aligned with investor expectations. We also delivered focused training sessions on core development disciplines, including project management fundamentals in biotech and the use of the TPP as a strategic framework for IND planning, equipping teams with practical tools to navigate development with greater clarity and discipline.
Key Takeaway: Academic teams benefit most from structured external input at the earliest stages, before they have committed to a specific commercialization path. Early clarity on value proposition and stakeholder landscape saves months of misdirected effort and builds the confidence needed for first investor conversations.
Supporting a VC in Pressure-Testing Investment Plans
On the investment side, we've been assisting a venture capital firm to build and pressure-test development plans for emerging biotech opportunities. This involves evaluating early data, mapping potential value creation pathways, and stress-testing assumptions around technical milestones and timelines. The objective is to help investors make more informed seed-stage decisions that are not just based on scientific novelty, but on operational feasibility and strategic clarity.
Key Takeaway: Operational diligence is as important as scientific diligence. A compelling mechanism of action does not protect an investment from poor timeline planning, unclear regulatory strategy, or vendor dependencies that were never mapped. Identifying these gaps before close is far less costly than discovering them after.
What These Projects Have in Common
Across these three engagements, the work is different on the surface but driven by the same underlying need: the need to bridge the gap between what is scientifically possible and what is operationally executable. Whether advising a VC, coaching a founding team, or building BD strategy for an AI company, the question is always the same - how do we turn this into something real?
At BioVertex Consulting, we believe that translation is a skill, not a circumstance. It requires structured thinking, cross-functional experience, and the ability to see both the scientific detail and the strategic picture simultaneously. These projects are a reflection of that philosophy in practice.
Connecting the Dots
Across these projects, a common thread emerges: the need for translation: translating complex technology into partner value, translating academic science into a viable venture, and translating investor interest into executable development plans. At BioVertex Consulting, this is the space we love to operate in: helping innovators, founders, and investors navigate the strategy-science interface with clarity and precision.
📣 To learn how BioVertex Consulting can support you, reach out: